SPECIAL NOTICE
A -- Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry
- Notice Date
- 3/4/2002
- Notice Type
- Special Notice
- Contracting Office
- Department of Energy, Lawrence Livermore National Laboratory (DOE Contractor), Industrial Partnerships & Commercialization, 7000 East Avenue L-795, Livermore, CA, 94550
- ZIP Code
- 94550
- Solicitation Number
- Reference-Number-FBO02-004-291
- Response Due
- 4/19/2002
- Archive Date
- 4/20/2002
- Point of Contact
- Connie Pitcock, Administration, Phone 925-422-1072, Fax 925-423-8988, - Laureen Stephens, Admin. Assistant, Phone 925-422-5077, Fax 925-423-8988,
- E-Mail Address
-
pitcock1@llnl.gov, stephens24@llnl.gov
- Description
- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS PARTNERSHIPS WITH INDUSTRY TO COMMERCIALIZE ITS INVENTION IN BIOMEDICAL AND PHARMACEUTICAL APPLICATION OF ACCELERATOR MASS SPECTROMETRY Announcement: Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is seeking industrial partners to commercialize LLNL's patent technologies on biomedical and pharmaceutical applications of accelerator mass spectrometry (AMS). Broad patent positions are held on such applications in both US and Canada. The patent technologies enable quantitative analysis of elemental composition of biomedical samples. In particular, the technologies allow the detection of low level radioactive trace elements, such as 3H and 14C, as long as the trace element concentration is about one hundred times higher than the background. With AMS, the patent technologies enable accurate study of metabolic kinetics of pharmaceutical compounds that can not be achieved by other commercially available detection methods. More detailed information on the technology can be found in US patents 5,376,355, 5,366,721, and 5,209,919. LLNL wants to license the technology to industrial partners that have demonstrated capability to deliver the technologies to the market. With a suitable arrangement, LLNL intends to provide industrial partners corresponding technologies such as complete sample characterization, sample preparation, and data acquisition and logging systems. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry should provide a written statement of interest including a commercialization plan and a description of corporate capabilities relevant to commercializing the technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P.O. Box 808, L-795 Livermore, CA 94551-0808 Attention: FBO02-004/291. Please provide your written statement within forty-five (45) days from the date this announcement is published to ensure consideration of your interest in LLNL's Biomedical and Pharmaceutical Application of Accelerator Mass Spectrometry
- Record
- SN00035013-W 20020306/020304213115 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |